The Role of Statistics in Preclinical Peptide Research

Preclinical peptide research generates large volumes of quantitative data: binding affinities, receptor occupancy curves, dose-response relationships, and selectivity ratios across receptor panels. Each of these measurements carries inherent variability, and the tools of inferential statistics exist to help researchers distinguish signal from noise. Yet those same tools are frequently misapplied, misreported, or misunderstood — sometimes in ways that allow statistical artifacts to masquerade as biological discoveries.

This article provides a structured reference for understanding the core statistical concepts that govern peptide research interpretation. It is directed at researchers, reviewers, and informed readers who encounter p-values, confidence intervals, and significance thresholds in the preclinical literature and wish to evaluate those claims with appropriate critical judgment.

What a P-Value Actually Measures

The p-value is perhaps the most cited and most misinterpreted number in biomedical research [1]. In formal terms, the p-value is the probability of observing a result at least as extreme as the one obtained, assuming the null hypothesis is true. It is not the probability that the null hypothesis is false, nor is it the probability that the finding will replicate, nor a measure of effect magnitude.

A p-value of 0.04 in a peptide binding assay does not mean there is a 96% chance the peptide genuinely binds the target. It means that, if binding were purely a product of random variation, there would be a 4% chance of seeing data this extreme by chance alone [1]. That is a subtler and considerably weaker statement than the one often implied in research summaries.

The conventional alpha threshold of 0.05 — the cutoff below which a result is deemed statistically significant — is a historical convention, not a law of nature. It was proposed by Ronald Fisher in the 1920s as a rough heuristic and has since calcified into a binary gatekeeping mechanism that the original framework never intended [6]. The American Statistical Association has explicitly cautioned against treating p < 0.05 as a definitive criterion for scientific truth [6].

The Null Hypothesis and Its Limitations in Peptide Contexts

In a typical peptide binding study, the null hypothesis might state that a modified peptide variant shows no difference in receptor affinity compared to a reference compound. Rejecting that null hypothesis at p < 0.05 establishes only that the observed difference is unlikely under the assumption of no effect. It does not establish the direction, magnitude, or biological relevance of that difference.

This distinction matters considerably when evaluating structural analogue screens, where dozens of peptide variants may be tested against the same receptor and small numerical differences in IC₅₀ values are reported as statistically significant without accompanying discussion of whether those differences carry any functional consequence.

The Multiple Comparison Problem

One of the most consequential statistical issues in peptide research is the inflation of false positive rates when multiple comparisons are conducted simultaneously [2]. Consider a receptor selectivity panel in which a novel peptide is tested against twenty receptor subtypes. If each individual test is conducted at α = 0.05, the probability of obtaining at least one false positive across all twenty tests — even if the peptide has no real activity at any receptor — rises to approximately 64%. This is not a flaw in the data; it is an arithmetic consequence of repeated testing.

The same problem arises in high-throughput peptide screening studies, where libraries of hundreds or thousands of structural variants are evaluated for binding or functional activity. Without correction for multiple comparisons, a substantial fraction of the reported hits will be statistical noise rather than genuine leads [2].

Bonferroni Correction and Its Trade-offs

The Bonferroni correction addresses this problem by dividing the alpha threshold by the number of comparisons performed. In a twenty-receptor panel, each individual test would need to reach p < 0.0025 to be considered significant at the family-wide α = 0.05 level. This approach is conservative by design: it minimises false positives (Type I errors) at the cost of increasing false negatives (Type II errors), meaning some genuine effects may be missed.

For peptide screening applications where the cost of pursuing false leads is high, Bonferroni correction provides a defensible standard. For exploratory studies where the goal is hypothesis generation rather than confirmation, its stringency may be excessive.

False Discovery Rate Control

The Benjamini-Hochberg procedure for controlling the false discovery rate (FDR) offers a more balanced alternative, particularly for large-scale peptide variant screens [3]. Rather than controlling the probability of any false positive, FDR control limits the expected proportion of false positives among all results declared significant. At an FDR threshold of 5%, one would expect approximately 5% of reported hits to be false positives — a tolerable rate in an exploratory screening context where downstream validation is anticipated.

FDR correction has become standard practice in genomic and proteomic research and is increasingly applied in peptide library screening. Its adoption in receptor pharmacology and binding studies remains inconsistent, which contributes to the replication difficulties discussed later in this article.

Type I and Type II Errors in Binding and Efficacy Studies

Statistical errors in peptide research take two forms. A Type I error — a false positive — occurs when a null hypothesis is incorrectly rejected: a peptide appears to show significant binding or activity when none exists. A Type II error — a false negative — occurs when a real effect is missed because the study lacked sufficient sensitivity.

In dose-response studies, Type I errors often arise from variability in assay conditions, batch effects in peptide synthesis, or inconsistent receptor preparation. A single experiment showing a statistically significant shift in EC₅₀ for a modified peptide may reflect genuine potency enhancement — or it may reflect a preparation artefact that will not reproduce under independent conditions.

Type II errors are equally consequential. An underpowered study that fails to detect a real difference between two peptide variants may lead to premature abandonment of a structurally promising scaffold. The asymmetry in how these errors are treated in publication — false positives reach journals more readily than null results — creates a systematic bias in the published literature [2].

Statistical Power and Sample Size

Statistical power is the probability that a study will detect a true effect of a given magnitude. A study with 80% power has an 80% chance of producing a statistically significant result when the effect being studied is real. Power depends on three factors: the alpha threshold, the expected effect size, and the sample size.

Preclinical peptide studies frequently operate with small sample sizes — three to six independent replicates is common in binding and cell-based assays — which can result in power levels well below 80% for modest effect sizes [5]. Button and colleagues demonstrated that the median statistical power in neuroscience studies was approximately 21%, meaning that the majority of studies in that field were structurally incapable of reliably detecting the effects they were designed to measure [5].

A related consequence of underpowered studies is effect size inflation. When a study with low power happens to produce a statistically significant result, it is often because random variation produced an unusually large observed effect. This phenomenon — sometimes called the winner's curse — means that effect sizes reported in initial, underpowered studies tend to shrink substantially upon replication [5].

For peptide researchers, this has a practical implication: a binding assay showing a tenfold improvement in affinity in a single experiment with n = 3 should be treated as a preliminary signal, not a confirmed finding. Formal power calculations prior to study design, using effect sizes derived from pilot data or prior literature, provide a more defensible basis for interpreting results.

Confidence Intervals as a Richer Alternative

Confidence intervals communicate what p-values cannot: the magnitude of an effect and the precision with which it has been estimated [4]. A 95% confidence interval around an IC₅₀ value indicates the range within which the true parameter is likely to fall, given the data and the model assumptions. Two peptide variants may both show statistically significant binding relative to a vehicle control, but if one has a narrow confidence interval and the other a wide one, the practical implications differ substantially.

In dose-response studies, overlapping confidence intervals for EC₅₀ estimates across structural analogues provide a more informative comparison than a table of p-values. A peptide with an EC₅₀ of 12 nM (95% CI: 9–16 nM) is more precisely characterised than one with an EC₅₀ of 10 nM (95% CI: 2–48 nM), even if both achieve nominal statistical significance.

Cumming's work on the new statistics advocates for a shift toward estimation-based reporting — confidence intervals, effect sizes, and meta-analytic summaries — as a more informative framework than binary significance testing [4]. This approach is particularly well suited to peptide pharmacology, where the goal is often to rank structural modifications by potency rather than simply to confirm that activity exists.

Effect Size: Separating Statistical from Biological Significance

Statistical significance and biological significance are not synonymous. A peptide modification that produces a statistically significant 1.1-fold increase in receptor binding affinity in a large, well-powered study may have no meaningful pharmacological consequence. Conversely, a threefold improvement in selectivity ratio that falls just short of p < 0.05 in a small study may represent a genuinely important structural insight.

Effect size metrics provide a standardised way to quantify the magnitude of an observed difference independent of sample size. Cohen's d expresses the difference between two means in units of standard deviation; a d of 0.2 is conventionally small, 0.5 medium, and 0.8 large. In peptide research, fold-change in IC₅₀ or EC₅₀ values is a more domain-relevant measure of effect size, as it maps directly onto pharmacological potency.

Reporting effect sizes alongside p-values — and alongside confidence intervals on those effect sizes — gives readers the information needed to assess whether a statistically significant finding is also biologically meaningful. The absence of effect size reporting in many preclinical peptide publications represents a gap in the current literature that reviewers and journals are increasingly moving to address.

Common Statistical Pitfalls in Preclinical Peptide Studies

P-Hacking and Selective Reporting

P-hacking refers to the practice of conducting multiple analyses on a dataset and reporting only those that achieve statistical significance. In a peptide screening context, this might involve testing multiple concentration ranges, selecting favourable time points, or excluding outlier replicates without pre-specified criteria — then presenting the resulting p < 0.05 as though it emerged from a single planned analysis [2].

Selective reporting operates at the study level: experiments that yield significant results are submitted for publication, while null results remain unpublished. The cumulative effect is a published literature that systematically overrepresents positive findings, creating a distorted picture of how reliably peptide modifications translate into measurable effects [7].

Post-Hoc Hypothesis Generation

A related problem is the presentation of post-hoc hypotheses as a priori predictions. A researcher who observes an unexpected pattern in receptor selectivity data and then frames that observation as a hypothesis test — without acknowledging that the hypothesis was generated by the same data used to test it — is engaging in a practice sometimes called HARKing (Hypothesising After Results are Known). This inflates false positive rates because the data have effectively been used twice: once to generate the hypothesis and once to confirm it.

Transparent reporting of whether analyses were pre-specified or exploratory is a minimal standard that allows readers to calibrate their confidence in reported findings appropriately.

Reproducibility and the Replication Standard

The translational record of preclinical research provides sobering context for interpreting statistical significance in peptide studies. Begley and Ellis reported that only 6 of 53 landmark preclinical oncology studies — many involving peptide and small-molecule compounds — could be reproduced by an internal team at Amgen, despite the original publications meeting conventional standards for statistical significance [7].

This failure rate does not indicate fraud; it reflects the cumulative effect of underpowered studies, multiple comparisons, publication bias, and the inherent variability of biological systems. A single statistically significant finding in a preclinical peptide study is a hypothesis, not a conclusion. Independent replication — ideally in a different laboratory, using independently synthesised compound and independently prepared biological material — is the standard against which preclinical claims should ultimately be evaluated.

For research compounds under investigation, this standard is particularly important. Early-stage research has explored numerous peptide scaffolds that showed compelling preclinical statistics before failing to reproduce under more rigorous conditions. The statistical significance of a binding assay result is a necessary but not sufficient condition for advancing a compound toward further investigation.

Toward More Rigorous Statistical Practice

Several practical standards, if consistently applied, would substantially improve the reliability of statistical inference in preclinical peptide research. Pre-registration of study designs and analysis plans — specifying hypotheses, sample sizes, and statistical methods before data collection — eliminates the ambiguity between confirmatory and exploratory analysis. Reporting confidence intervals and effect sizes alongside p-values provides readers with the information needed to assess biological relevance. Applying appropriate multiple comparison corrections in screening studies reduces the false positive burden. And treating initial findings as requiring independent replication before drawing strong conclusions reflects the epistemic reality of preclinical research.

Statistical significance is a tool for managing uncertainty, not a mechanism for resolving it. A p-value below 0.05 is an invitation to investigate further, not a certificate of biological truth. Understanding the limits of that tool is as important as knowing how to apply it.

All compounds referenced in this article in the context of preclinical studies are research compounds. Findings discussed are drawn from the published scientific literature and represent early-stage research only. No therapeutic claims are made or implied.